Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
Celltrion Healthcare`s Omlyclo (omalizumab) Receives Approval in the Europe
The European Commission (EC) has approved Celltrion’s Omlyclo (CT-P39) – the first and only omalizumab biosimilar for reference product Xolair to be authorised in Europe to treat allergic conditions.
Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe
Celltrion USA completes submission of BLA to U.S. FDA for CT-P39
Feb 25 (Reuters) - Xolair, a 20-year-old asthma drug sold by Roche (ROG.S), opens new tab and Novartis (NOVN.S), opens new tab, significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting.
Xolair becomes first medicine approved in US for food allergy
Genentech`s Biologic Xolair (omalizumab) Receives Approval in the U.S.